A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Rosenberg AJ, Liao CY, Karrison T, de Souza JA, Worden FP, Libao B, Krzyzanowska MK, Hayes DN, Winquist E, Saloura V, Prescott K, Villaflor VM, Seiwert TY, Schechter RB, Stadler WM, Cohen EEW, Vokes EE.
Rosenberg AJ, et al. Among authors: schechter rb.
Ann Oncol. 2023 Aug;34(8):714-722. doi: 10.1016/j.annonc.2023.05.002. Epub 2023 May 13.
Ann Oncol. 2023.
PMID: 37182801
Free PMC article.
Clinical Trial.